What CE IVD means under the IVDR
CE IVD refers to an in vitro diagnostic medical device that bears the CE marking for access to the EU market. Under Regulation (EU) 2017/746, the In Vitro Diagnostic Medical Devices Regulation or IVDR, the mark is not just a label claim. It is the manufacturer’s declaration that the device meets the applicable EU requirements after the correct conformity assessment route has been completed.
For most IVD portfolios, that route now depends on risk classification, performance evaluation, technical documentation, quality management, post-market surveillance and, for many devices, a notified body certificate. Regulation (EU) 2024/1860 extended some IVDR transition periods, but it did not remove the need to prepare for full IVDR compliance.
For related regulatory updates, see the Regulatory section.
An IVD may be a reagent, kit, calibrator, control material, instrument, software or system intended to examine human specimens for a medical diagnostic purpose. The regulatory position depends on the intended purpose assigned by the manufacturer, not only on the technology, specimen type or analyte. For that reason, the first step in a CE IVD project is not finding a certificate route. It is defining the product claim precisely enough to determine whether the product falls within the IVDR and which class applies.
Why CE IVD marking became more demanding
The IVDR replaced the previous In Vitro Diagnostic Medical Devices Directive, commonly called the IVDD, and changed the basis of IVD compliance. The IVDD relied more heavily on lists and allowed many IVDs to be self-declared. The IVDR introduced a rule-based classification system with four risk classes: A, B, C and D. Class A represents the lowest risk, while class D covers the highest individual and public health risk.
In practice, many devices that were previously self-declared now require notified body involvement. The European Commission’s manufacturer information has repeatedly highlighted three major changes: a new risk-based classification model, broader notified body oversight, and stronger clinical evidence expectations. Performance evaluation is also more structured under the IVDR. Manufacturers must address scientific validity, analytical performance and clinical performance, then maintain the evidence throughout the product life cycle.
This distinction matters because “CE IVD” is often used as a commercial phrase, while the route behind it is regulatory. A CE-marked IVD should be supported by an EU declaration of conformity, technical documentation, risk management, performance evaluation, appropriate labelling and post-market processes. Where a notified body is required, the CE marking is also linked to the notified body’s conformity assessment and identification number.
Current IVDR transition deadlines for legacy IVDs
Regulation (EU) 2024/1860, signed on 13 June 2024 and published in the Official Journal on 9 July 2024, amended the IVDR transition rules. As of October 2026, the key point is that the extension is conditional. It does not apply to every product, and it does not allow a manufacturer to wait until the final placing-on-the-market date before starting IVDR work.
Legacy devices may benefit only where the relevant conditions are met. In broad terms, the device must continue to comply with the IVDD, must not undergo significant changes in design or intended purpose, must not present an unacceptable health or safety risk, and must follow the applicable IVDR requirements for post-market surveillance, vigilance, market surveillance and registration. Manufacturers also had to put in place an IVDR-compliant quality management system by 26 May 2025.
| Legacy IVD situation | Latest placing on the market or putting into service date | Key transition action |
|---|---|---|
| Devices with a qualifying IVDD notified body certificate | 31 December 2027 | Maintain transition conditions and proceed with IVDR conformity assessment |
| Legacy devices that were IVDD self-declared but are IVDR class D | 31 December 2027 | Formal notified body application deadline was 26 May 2025; written agreement deadline was 26 September 2025 |
| Legacy devices that were IVDD self-declared but are IVDR class C | 31 December 2028 | Formal notified body application deadline was 26 May 2026; written agreement deadline is 26 September 2026 |
| Legacy devices that were IVDD self-declared but are IVDR class B or class A sterile | 31 December 2029 | Formal notified body application deadline is 26 May 2027; written agreement deadline is 26 September 2027 |
These dates are often misunderstood. The final transition date is not the date to begin building the file. For class C devices, for example, the notified body application deadline had already passed by October 2026, and the written agreement deadline was 26 September 2026. For class B and class A sterile legacy devices, the 2029 final date still depends on meeting earlier application and agreement milestones.
New IVDs and class A non-sterile devices that do not qualify as legacy devices have generally needed to comply with the IVDR since 26 May 2022. Manufacturers should therefore separate their portfolios into at least three groups: devices already CE marked under the IVDR, legacy devices still using transition provisions, and products that require a full IVDR route before they can be placed on the EU market.
How the CE IVD route differs by class
Classification drives the CE IVD strategy. The current MDCG classification guidance, including MDCG 2020-16 rev.5 issued in September 2026, reinforces that all implementing rules and classification rules must be considered. The intended purpose remains central. Software, accessories, calibrators and control materials can also affect classification, especially when they drive, influence or support the use of another IVD.
| IVDR class | Typical conformity assessment implication | Practical planning point |
|---|---|---|
| Class A non-sterile | Manufacturer self-declaration after meeting IVDR requirements | Still requires technical documentation, performance evidence, QMS elements and an EU declaration of conformity |
| Class A sterile | Notified body involvement for sterility-related aspects | Sterile packaging, sterilization validation and maintenance of sterile conditions need early attention |
| Class B | Notified body conformity assessment required | Evidence gaps should be addressed before application because notified body review capacity can affect timing |
| Class C | Notified body conformity assessment required, generally with deeper technical documentation sampling | Claims, specimen type, population and clinical performance data should be tightly aligned |
| Class D | Highest-risk route with notified body involvement and, where applicable, EU reference laboratory input | Plan for longer timelines, batch verification considerations and more intensive performance evaluation expectations |
Companion diagnostics have an additional step because notified bodies must consult the relevant medicinal products authority or the European Medicines Agency in defined circumstances. For high-risk class D devices, EU reference laboratory involvement may also apply where a laboratory has been designated for that device type. These steps can affect both review duration and evidence expectations.
What a CE IVD file should normally cover
A strong IVDR file is built around traceability between intended purpose, classification, claims, risks, performance evidence, labelling and post-market controls. It should not read like a set of unrelated reports. It should show how the manufacturer reached the conclusion that the device conforms to the IVDR requirements.
- Qualification and intended purpose: Explain why the product is an IVD or an accessory to an IVD, and define the medical purpose, target population, user, specimen type and testing environment.
- Classification rationale: Apply Annex VIII rules and document why the chosen class is appropriate, including any rules considered but not applied.
- Quality management system: Cover design control, supplier control, risk management, complaint handling, vigilance, post-market surveillance and performance evaluation processes.
- General safety and performance requirements: Map each applicable requirement to objective evidence, standards, tests, analyses or justifications.
- Performance evaluation: Address scientific validity, analytical performance and clinical performance, then define post-market performance follow-up where needed.
- Technical documentation: Maintain device description, design and manufacturing information, risk management, verification and validation evidence, labels, instructions for use and post-market documentation.
- EU declaration of conformity: Prepare the declaration only after the applicable conformity assessment route has been completed.
- Economic operator controls: Confirm importer, distributor and authorised representative obligations where the manufacturer is outside the EU or EEA.
The most common weakness is a mismatch between claims and evidence. If the label, instructions for use or promotional material suggests a broader clinical use than the studies support, the CE IVD file becomes vulnerable. A narrow, well-supported intended purpose is usually more defensible than a broad claim backed by incomplete data. See also: Implants.
EUDAMED, supply obligations and post-market control
CE marking does not end at certification or declaration. The IVDR is built around life-cycle control. Post-market surveillance, vigilance and performance follow-up must feed back into risk management and performance evaluation. Corrective actions, trend reporting and field safety actions should be managed through documented procedures rather than treated as one-off events.
EUDAMED is also becoming more relevant in daily regulatory work. According to the European Commission’s EUDAMED status information, four modules became mandatory from 28 May 2026: actor registration, UDI/device registration, notified bodies and certificates, and market surveillance. The remaining modules for vigilance and post-market surveillance, and for clinical investigations and performance studies, are still being developed. Manufacturers should treat registration data quality as part of regulatory compliance, not as an administrative afterthought.
Another current requirement is the interruption or discontinuation of supply obligation introduced through Article 10a by Regulation (EU) 2024/1860. From 10 January 2025, where a manufacturer anticipates interruption or discontinuation of supply of certain devices and serious harm or a risk of serious harm to patients or public health is reasonably foreseeable, information must be provided to the relevant competent authority and directly supplied economic operators, health institutions or healthcare professionals. For IVD manufacturers, this links regulatory planning with supply-chain risk management.
Common mistakes in CE IVD planning
The first mistake is assuming that a transition extension is the same as an exemption. It is not. Legacy status is conditional, and design or intended-purpose changes can jeopardize the transition pathway. Manufacturers should assess changes against the relevant MDCG guidance before implementation, especially if the device is still relying on an IVDD certificate or declaration.
The second mistake is classifying by product family or technology alone. Under the IVDR, the same analyte or platform can fall into a different class when the intended purpose, specimen, user, testing environment or patient-management role changes. A software module that influences interpretation may also need its own classification analysis.
The third mistake is approaching the notified body too late. A complete application is more than a form. It depends on a coherent QMS, sufficient performance evidence, technical documentation and an achievable review plan. Manufacturers should also verify that the notified body’s designation scope covers the relevant IVDR codes for the device type.
The fourth mistake is treating the EU declaration of conformity as the main evidence of compliance. The declaration is the outcome of conformity assessment, not the foundation. Authorities, notified bodies, importers and distributors may need to see the basis for the declaration, including classification rationale, certificates where applicable, and documentation showing that post-market obligations are active.
Frequently asked questions
Does CE IVD mean the device is approved by the FDA?
No. CE IVD marking relates to EU regulatory conformity. It is separate from US FDA clearance, approval or authorization. A device may need different evidence, submissions and labelling controls for the United States, the European Union and other markets.
Can a class A non-sterile IVD be self-declared?
Yes, if the device is correctly classified as class A non-sterile and all IVDR requirements are met. Self-declaration does not mean no documentation. The manufacturer still needs an appropriate quality system, technical documentation, performance evidence, post-market processes and an EU declaration of conformity.
Are IVDD certificates still usable?
Some IVDD certificates may remain usable under the IVDR transition rules only if the legal conditions are met. The device must continue to comply with the IVDD, avoid significant design or intended-purpose changes, avoid unacceptable risk, and meet the applicable IVDR obligations and deadlines. The final endpoint for qualifying IVDD certificates is 31 December 2027.
What happens if a legacy IVD has a significant change?
A significant change in design or intended purpose can prevent the device from continuing to rely on the transition provisions. Manufacturers should document change assessments carefully and consider the relevant MDCG significant-change guidance before making changes to a legacy device.
What is the practical takeaway for CE IVD planning?
Start with intended purpose and classification, then build the evidence and conformity route around that decision. For legacy devices, map the transition conditions and deadlines immediately. For new or changed devices, plan for full IVDR compliance rather than assuming that transition rules will apply.